Fundraising FoxBiotech Startups
11,050 companies tagged Biotech, with their investors and founders.
0 investors
0 investors
Fina BioSolutions produces CRM197 carrier proteins used in vaccine development and research, offering both research-grade and cGMP-certified versions through an efficient E. coli expression system.
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
FLAG Therapeutics develops drug delivery and dosage form solutions for pharmaceutical development and manufacturing, serving biotech and pharmaceutical companies in oncology and rare disease therapeutics.
0 investors
0 investors
Flavocure Biotech is a biotechnology company developing flavonoid-derived compounds from cannabis as therapeutics for cancers such as metastatic pancreatic cancer and other conditions. It conducts preclinical drug research and development.
0 investors
Florey Biosciences uses synthetic biology to engineer precision probiotics for human health, with a lead product, FLR-101, an engineered food-grade yeast probiotic developed as a medical food to manage antibiotic-related disruptions of the gut microbiome. It targets patients taking antibiotics and operates in the synthetic biology and microbiome therapeutics space.
0 investors
0 investors
Flow Pharma develops immunotherapy treatments and vaccines using T-cell-stimulating technology to prevent and treat cancer and viral diseases such as COVID-19, Ebola, and Marburg. The company focuses on drug development and manufacturing in the biotech and medical research space.
0 investors
0 investors
FluoroFinder offers an AI-enabled platform for designing flow cytometry and fluorescent microscopy experiments, analyzing marker and fluorophore combinations across more than 3 million products from 78+ suppliers. It serves researchers, labs, and core facilities to select compatible reagents and plan experiments within their lab's configuration.
0 investors
0 investors
0 investors
0 investors
Foment Bio develops non-viral, off-the-shelf plasmid gene therapy constructs that trigger in vivo production of regenerative exosomes to restore tissue microvasculature, resolve inflammation, and prevent cell death. The therapy targets age-related and cardiometabolic chronic diseases including heart failure, chronic kidney disease, erectile dysfunction, and wound healing, and has advanced into FDA clinical trials.
0 investors